David DiLillo
Executive Director, Immune-Oncology Regeneron
David DiLillo is a broadly-trained immunologist with more than 24 years of experience in basic and translational biomedical sciences. He brings expertise in the areas of tumor immunology, infectious disease, and autoimmunity, with particular emphasis in immuno-oncology, T cell-engaging antibodies, adoptive cellular therapies (CAR T and TCR T), antibody biology/engineering, Fc-receptor biology, B- and T-lymphocyte biology, and immunological regulatory mechanisms.
Seminars
Wednesday 10th June 2026
Bispecific Antibody Combinations for Optimized Anti-Tumor Activity in Liquid & Solid Tumors
4:30 pm
- Co-localizing "signal 1" (TCR) and "signal 2" (co-stimulation) within the tumor microenvironment to drive optimized anti-tumor responses
- Integrating signal 3 (cytokine support) for even deeper anti-tumor responses
- Preclinical and clinical data support rational combinations with biologics in patients
